ARTES and Rhein Minapharm continue their successful product development collaboration
ARTES Biotechnology and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE, jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009.
ARTES applied for this research collaboration its proprietary Hansenula technology platform and know-how to the generation of a therapeutic protein chosen by Rhein Minapharm that is typically produced in E coli. Rhein Minapharms´s new target is now produced from the Hansenula polymorpha platform at considerable higher yields and at reduced costs compared to alternative bacterial or yeast systems.
Under the terms of agreement ARTES handed over the production cell lines and received another milestone payment. Additionally, ARTES and Rhein Minapharm extended their collaboration aiming at additional targets for Minapharm´s portfolio. ARTES will be responsible for the generation of new production cell lines and will share the process research and development responsibility with Minapharm.
Other news from the department business & finance
